Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of AbGn-168H Administered by Intravenous Infusion to Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Double-blind, Placebo-controlled)
Latest Information Update: 22 Apr 2021
At a glance
- Drugs Neihulizumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors AbGenomics Corporation; AltruBio
- 11 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Aug 2014 New trial record